Evidence map›Paper›PMID 42571564›Full record

ArticleAnnals of intensive care2026

Early red blood cell transfusion burden, hemoglobin at first transfusion, and in-hospital mortality in patients supported with veno-arterial ECMO: a multicenter cohort study.

Min Ho Ju, Seulgi Ju, In Seok Jeong, Hyoung Soo Kim, Yang Hyun Cho, Jae-Seung Jung, Jung-Hoon Shin, Sunghyun Sim, Hee Jung Kim

Abstract read
In one paragraph

Article in Annals of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Min Ho JuDepartment of Thoracic and Cardiovascular Surgery and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Seulgi JuGraduate School of AI Convergence Engineering, Changwon National University, 20 Changwondaehak-ro, Uichang-Gu, 51140 Changwon, South Korea.
In Seok JeongDepartment of Thoracic and Cardiovascular Surgery, Chonnam National University Hospital, Gwangju, South Korea.
Hyoung Soo KimDepartment of Thoracic and Cardiovascular Surgery, Hallym University Sacred Heart Hospital, Hallym University Medical Center, Anyang-si, Gyeonggi-do 14068, Republic of Korea.
Yang Hyun ChoDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Republic of Korea.
Jae-Seung JungDepartment of Thoracic and Cardiovascular Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
Jung-Hoon ShinDivision of Cardiovascular Surgery, Department of Cardiovascular and Thoracic Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea.
Sunghyun SimDepartment of AI Convergence Engineering, Changwon National University 20 Changwondaehak-ro, Uichang Gu, 51140 Changwon, South Korea.
Hee Jung KimDepartment of Thoracic and Cardiovascular Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Red blood cell (RBC) transfusion is common during venoarterial extracorporeal membrane oxygenation (VA-ECMO), but the prognostic relevance of early cumulative transfusion burden and hemoglobin (Hb) at transfusion initiation remains uncertain. We examined associations of ECMO day-1 RBC dose and, among transfused patients, first-transfusion Hb and transfusion-pattern phenotype with in-hospital mortality. Methods: Adults aged ≥18 years initiating peripheral VA-ECMO at six Korean centers between January 2018 and March 2025 were analyzed. The primary analysis used a 24 -h landmark cohort of patients alive and still receiving ECMO beyond 24 h. Day-1 RBC dose was categorized as 0, 1-2, 3-4, or ≥5 units and modeled per 2-unit increase. Adjusted risk ratios (RRs) were estimated using modified Poisson regression. Secondary analyses assessed first-transfusion Hb and consistent- versus variable threshold phenotypes among transfused complete cases. Results: Among 2,020 included patients, 1,708 entered the 24-h landmark cohort, and 1,140 complete cases comprised the adjusted primary analysis. Compared with no day-1 transfusion, adjusted RRs for in-hospital mortality were 1.20 (95% confidence interval [CI], 1.02-1.40) for 1-2 units, 1.37 (95% CI, 1.17-1.59) for 3-4 units, and 1.48 (95% CI, 1.28-1.71) for ≥5 units. Each 2-unit increase was associated with higher mortality (adjusted RR, 1.08; 95% CI, 1.05-1.11), with concordant findings over ECMO days 1-2 (adjusted RR, 1.06; 95% CI, 1.04-1.08). Among 1,043 transfused complete cases with qualifying pretransfusion Hb, each 1 g/dL decrease in first-transfusion Hb was associated with higher mortality (adjusted RR, 1.15; 95% CI, 1.10-1.20). The association was evident in the consistent-threshold phenotype (adjusted RR, 1.16; 95% CI, 1.10-1.22) but not in the variable-threshold phenotype (adjusted RR, 1.02; 95% CI, 0.92-1.12). Conclusions: In adults receiving peripheral VA-ECMO, early RBC transfusion burden showed a graded association with in-hospital mortality, whereas lower first-transfusion Hb was a prognostic marker chiefly within the consistent-threshold phenotype. These findings support dose- and threshold-aware prognostic assessment but do not establish causality or define an optimal transfusion threshold.

Indexed as

Hemoglobin thresholdIn-Hospital mortalityRed blood cell transfusionTransfusion strategyVeno-Arterial extracorporeal membrane oxygenation

Identifiers

PMID42571564
PMCPMC13452410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.